Navigation Links
New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes
Date:4/23/2010

e treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis.  Welchol has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones.  Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.  Welchol has not been studied in children younger than 10 years of age or in pre-menarchal girls.  Welchol is available in two formulations, Welchol tablets and Welchol® for Oral Suspension.

In clinical studies of adult patients with type 2 diabetes, Welchol lowered A1C, fasting plasma glucose and LDL-C, important risk factors for cardiovascular disease.*  In clinical studies of patients with elevated LDL-C, Welchol lowered LDL-C when used as monotherapy, when added to statin therapy, or as initial combination with statin therapy.(2)

*The effect of Welchol on cardiovascular morbidity and mortality has not been determined.

IMPORTANT INFORMATION ABOUT WELCHOL (colesevelam HCl)

Indications

Welchol is indicated as an adjunct to diet and exercise to:

  • reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia (Fredrickson Type IIa) as monotherapy or in combination with an hydroxymethyl-glutaryl-coenyme (HMG CoA) reductase inhibitor
  • reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia, as monotherapy or in combination with a statin after failing an adequate trial of diet therapy
  • improve glycemic control in adults with type 2 diabetes mellitus

Important Limitati
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
2. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
3. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
4. New Data Demonstrates Abbotts Investigational MitraClip(R) System Has Potential to be a Valuable Treatment Option for Patients With Mitral Regurgitation, the Most Common Heart Valve Condition
5. New Study Demonstrates Safety of Balloon Sinuplasty(TM) Technology in Pediatric Patients Suffering From Chronic Sinusitis
6. Tobiras Next-Generation Once-Daily CCR5 Receptor Antagonist Demonstrates Efficacy, Safety and Tolerability in Treatment-Experienced Patients With HIV
7. NovaShunt Starts its Pivotal Clinical Study "PIONEER" to Demonstrate the Clinical Value of the AFS System
8. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
9. Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines
10. AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs
11. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... January 23, 2015 Heptares Therapeutics, the clinical-stage ... announce that the Malcolm Campbell Memorial Prize for ... President of Chemistry), Fiona Marshall (Chief Scientific Officer ... and co-founder) for the seminal contributions to GPCR drug discovery ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to announce ... Vice President of Chemistry and Biochemistry. Scott joins the company ... Pharmaceuticals, and Amgen throughout the course of his nearly ... "Scott is a nationally recognized thought leader in ...
(Date:1/22/2015)... ON , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular disease and ... of the Company,s accomplishments in 2014 and its outlook for ... Dear Fellow Shareholders, We would like to ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... Jan. 19, 2011 RFID Journal features ... Someone can live or die depending on the ... agree leveraging better tracking of a drug,s expiration dates, ... levels, all performed in REAL TIME, would assist in ...
... PRINCETON, N.J., Jan. 18, 2011 Pharmasset, Inc. (Nasdaq: ... commenced an underwritten public offering, subject to market and ... pursuant to an effective shelf registration statement.  Of the ... the selling stockholders are selling 1,000,000 shares.  Pharmasset intends ...
Cached Medicine Technology:MEPS Real Time's New RFID Drug Management System Provides Critical Error Solution for California Hospital 2Pharmasset Announces Proposed Public Offering of Common Stock 2Pharmasset Announces Proposed Public Offering of Common Stock 3
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted living ... p.m. to 4 p.m. on Feb. 13. , The community, which ... with physical disabilities between the ages of 22 and 64. , ... sweetheart-themed karaoke. , For more information about the event or Deer ...
(Date:1/22/2015)... Hawley, PA (PRWEB) January 22, 2015 Woodloch ... Pocono Mountains, has been selected by TripAdvisor as the number ... and the 6th best in the world for their annual ... online travel community . The website is home to ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering ... follow it on Facebook, Twitter, and Pinterest. The fans will ... draws a lottery every week. , Moreover, the company has ... Click Angelweddingdress homepage for more information. , ...
(Date:1/22/2015)... A new white paper by The ... in the long-term care environment as well as provides ... The paper, “The Power of Person-Centeredness in Long-Term Care: ... of the patient, resident and family experience in long-term ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (the ... final results of its separate concurrent fixed price exchange offers ... any and all of the approximately $118.9 million outstanding principal ... The Exchange Offers expired at 5:00 p.m., New York ...
... As President Obama prepares to sign a bill giving ... tobacco industry, a new study from Harvard School of ... continually changed the ingredients and the design of their ... acceptable product variance guidelines. The result, say the researchers, ...
... The Damon Runyon Cancer Research Foundation, a non-profit ... and innovative cancer research, named 17 new Damon ... Committee review. The recipients of this prestigious, three-year ... translational cancer research in the laboratories of leading ...
... in Williamson County ... Round Rock Medical Center today announced that the hospital will seek ... Williamson County. , , "St. David,s Round Rock Medical Center ... has the busiest emergency department in the City of Round Rock ...
... their choice , FRIDAY, June 19 (HealthDay News) -- ... can,t list any actual benefits, a new British study ... BMC Public Health , stemmed from interviews that University ... sports center. , "The majority of participants believed that ...
... WLP ) will release second quarter 2009 financial results on July 29, ... and its outlook during a conference call at 8:30 a.m. EDT that same ... its start with the following numbers: , , , ... 800-475-6701 (Domestic Replay), ...
Cached Medicine News:Health News:Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 2Health News:Cell Therapeutics Announces Final Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 3Health News:Study finds that tobacco companies changed design of cigarettes without alerting smokers 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 2Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 3Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 4Health News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 17 top young scientists 5Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 2Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 3Health News:St. David's Round Rock Medical Center to Seek Level II Trauma Designation 4Health News:WellPoint to Hold Conference Call and Webcast to Discuss Second Quarter Results on July 29, 2009 2